Application Nr Approved Date Route Status External Links
ANDA040151 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Promethazine Hcl And Codeine Phosphate Oral Solution Is Indicated For The Temporary Relief Of Coughs And Upper Respiratory Symptoms Associated With Allergy Or The Common Cold In Patients 18 Years Of Age And Older. Important Limitations Of Use: • Not Indicated For Pediatric Patients Under 18 Years Of Age [see Use In Specific Populations (8.4) ]. • Contraindicated In Pediatric Patients Under 12 Years Of Age [see Contraindications (4) , Use In Specific Populations (8.4) ]. • Contraindicated In Pediatric Patients 12 To 18 Years Of Age After Tonsillectomy Or Adenoidectomy [see Contraindications (4) , Use In Specific Populations (8.4) ]. • Because Of The Risks Of Addiction, Abuse, And Misuse With Opioids, Even At Recommended Doses [see Warnings And Precautions (5.1) ], Reserve Promethazine Hcl And Codeine Phosphate Oral Solution For Use In Adult Patients For Whom The Benefits Of Cough Suppression Are Expected To Outweigh The Risks, And In Whom An Adequate Assessment Of The Etiology Of The Cough Has Been Made. Promethazine Hcl And Codeine Phosphate Oral Solution Is A Combination Of Codeine, An Opioid Agonist, And Promethazine, A Phenothiazine, Indicated For The Temporary Relief Of Cough And Upper Respiratory Symptoms Associated With Allergy Or The Common Cold In Patients 18 Years Of Age And Older. (1) Important Limitations Of Use (1) • Not Indicated For Pediatric Patients Under 18 Years Of Age. • Because Of The Risks Of Addiction, Abuse, And Misuse With Opioids, Even At Recommended Doses, Reserve Promethazine Hcl And Codeine Phosphate Oral Solution For Use In Adult Patients For Whom The Benefits Of Cough Suppression Are Expected To Outweigh The Risks, And In Whom An Adequate Assessment Of The Etiology Of The Cough Has Been Made.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments